title: Effects of pentobarbital on t-[35S]butylbicyclophosphorothionate and [3H]flunitrazepam binding to membrane-bound and solubilized preparations from rat forebrain.
abstract: The binding sites for t-[35S]butylbicyclophosphorothionate ([35S] TBPS) and [3H]flunitrazepam ([3H]Flu) were solubilized from freshly prepared and washed membranes from rat forebrain with 20 mM 3-[(cholamidopropyl)-dimethylamonio]-1-propanesulfonate in the presence of protease inhibitors. Approximately 64% of the protein, 56% of the [35S]TBPS sites and 45% of the [3H] Flu sites were solubilized. The soluble and membrane-bound binding sites for [3H]Flu were relatively stable on storage at 0 degree C or at -65 degrees C for 11 days. Binding of [35S]TBPS to membranes was increased after freezing the membranes at -65 degrees C for 1 to 11 days and was relatively unchanged if the membranes were stored at 0 degree C for 1 to 11 days. Solubilized [35S]TBPS binding sites were stable when stored at -65 degrees C but declined to 20% of control when stored at 0 degree C for 11 days. Tested shortly after preparation, [35S]TBPS binding to both soluble and membrane preparations demonstrated similar affinity, temperature dependence and noncompetitive inhibition by pentobarbital (pb). Stimulation by pb of [3H]Flu binding to the soluble fraction decayed on storage of the solubilized material at 0 degree C with a time course similar to the loss of [35S]TBPS binding. This finding might suggest that the stimulation of [3H]Flu binding by pb is mediated via its action on TBPS sites. However in membrane preparations stored at 0 degree C, [35S]TBPS binding was stable whereas the pb effects declined with time.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: J A
authors.initials: JA
authors.lastname: Richter
authors.forename: H I
authors.initials: HI
authors.lastname: Yamamura
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D001643:Bridged Bicyclo Compounds / Q000378:metabolism*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds / Q000378:metabolism*; D002793:Cholic Acids; D005445:Flunitrazepam / Q000378:metabolism*; D007700:Kinetics; D010424:Pentobarbital / Q000494:pharmacology*; D051381:Rats; D011963:Receptors, GABA-A / Q000378:metabolism*; D017981:Receptors, Neurotransmitter / Q000378:metabolism*; D012995:Solubility; D013696:Temperature
chemical_list: D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds; D002793:Cholic Acids; D011963:Receptors, GABA-A; D017981:Receptors, Neurotransmitter; C030975:barbiturate receptor; D005445:Flunitrazepam; C037476:tert-butylbicyclophosphorothionate; D010424:Pentobarbital; C028213:3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate